← Leaderboards
John Crouse
Wake Forest University
$111,496
Attributed
$111,496
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$111,496 · 4
By mechanism
M01$111,496 · 4
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University
Same institution · by research overlap
- John R Crouse$7,936,079
- Michael R Adams$3,538,071
- Gregory L Burke$6,204,124
- Ross P Holmes$8,401,825
- David M Herrington$40,002,179
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectLow Density LipoproteinBlood ChemistryDrug Screening /EvaluationAntihypercholesterolemic AgentTriglyceridesNutrition Related TagCardiovascular Disorder PreventionHypercholesterolemiaLongitudinal Human StudyEnzyme InhibitorsFlavonesFolateGastrointestinal Nutrient AbsorptionGenisteinHigh Density LipoproteinsHmg Coa ReductasesMyocardial InfarctionMyocardial Ischemia /HypoxiaNutrient BioavailabilityOutcomes ResearchPharmacokinetics
Grant awards (4)
EVALUATE EFFICACY OF SIMVASTATIN AND ATORVASTATIN IN HYPERCHOLESTEROLEMIA$38,800
M01 · FY2000 · RR
BIOAVAILABILITY OF SOY ISOFLAVONE AGLYCON COMPARED TO CONJUGATED ISOF$24,232
M01 · FY2000 · RR
EFFICACY OF SIMVASTATIN THERAPY IN PATIENTS W/ HYPERTRIGLYCERIDEMIA$24,232
M01 · FY2000 · RR
HEART ACTIVITY &STROKE$24,232
M01 · FY2000 · RR